Past, Present, and Future Few compounds have had as winding a journey through medicine, counterculture, and federal regulation as MDMA.
Once an obscure chemical synthesized for industrial purposes, it became a quiet tool in psychotherapists’ offices, then a fixture of rave culture, and more recently the subject of one of the most closely watched drug approval battles in modern psychiatry. Its story offers a window into how science, law, and culture shape and sometimes derail the path a potential treatment takes.
The Past
From Chemical Curiosity to Underground Therapy Tool MDMA’s history begins far from any psychiatrist’s office. The compound was first synthesized in 1912 by the Merck pharmaceutical company, but its psychoactive properties went unnoticed for decades. That changed in the mid-1970s, when chemist Alexander Shulgin already known for his work with psychedelic and “entactogenic” compounds resynthesized MDMA and began experimenting with it himself, publishing the first account of its effects in humans in 1978. Shulgin shared the compound with therapists, and it found its way to Leo Zeff, a California psychotherapist with prior experience using a related compound, MDA, in his practice. Zeff went on to train roughly 150 therapists and reportedly treated over 4,000 patients with MDMA-assisted therapy before 1985, using it to help with trauma, relationship difficulties, depression, and addiction. During this same period, MDMA was migrating into recreational use first in niche scenes, then increasingly in nightclubs, where it became known as “Ecstasy.” The growing visibility of recreational use caught the attention of the Drug Enforcement Administration, which moved in 1984 to classify MDMA as a Schedule I substance. A group of clinicians and researchers challenged the move, and an administrative law judge who reviewed the evidence actually recommended a less restrictive Schedule III classification that would have preserved medical access. The DEA’s director overruled that recommendation, and in 1985 MDMA was placed in Schedule I the category reserved for substances deemed to have no accepted medical use and a high potential for abuse. The following year, MDMA was added to Schedule I of the UN Convention on Psychotropic Substances, making the prohibition global. This effectively ended the first era of MDMA-assisted psychotherapy. For roughly a decade and a half, formal research was nearly impossible, even as the drug’s recreational popularity grew alongside the rise of electronic dance music and rave culture.
The Present:
Decades of Trials Meet a Regulatory Wall The modern chapter of MDMA’s psychiatric story is largely the work of the Multidisciplinary Association for Psychedelic Studies (MAPS), founded in 1986 specifically to pursue a path back to legitimate medical research. Over the following decades, MAPS and later its associated company, eventually renamed Lykos Therapeutics built a body of clinical evidence for MDMA-assisted therapy (MDMA-AT) in posttraumatic stress disorder. That effort produced encouraging results. Across a series of six Phase 2 trials in treatment-resistant PTSD, 54% of participants who received full-dose MDMA no longer met the criteria for PTSD after two sessions, compared with 23% in the control group. The FDA took notice, granting MDMA-AT Breakthrough Therapy designation for PTSD in 2017. Two subsequent Phase 3 trials, published in 2021 and 2023, reinforced the signal: PTSD remission rates of 67% to 71% were reported with MDMA-assisted psychotherapy, compared with 32% to 48% in the placebo-assisted therapy groups. Building on that data, Lykos Therapeutics submitted a New Drug Application to the FDA in December 2023. The FDA accepted the application, granted it priority review, and set a target decision date of August 11, 2024 a moment many in the field expected would mark the first-ever FDA approval of a psychedelic-assisted therapy. Things did not go as planned. In June 2024, the FDA’s Psychopharmacologic Drugs Advisory Committee reviewed the application and voted decisively against it 9 to 2 against the treatment’s effectiveness, and 10 to 1 against the conclusion that its benefits outweighed its risks. In August 2024, the FDA followed that vote with a Complete Response Letter declining to approve the application and requesting an additional Phase 3 trial. The full details of that letter weren’t made public until September 2025, when the FDA released it as part of a broader push toward transparency in drug-approval decisions. The letter outlined three main areas of concern, eight specific safety issues, and nine suggestions for future trials. Among the problems cited: gaps in documenting abuse-related adverse events, inconsistencies in how therapy was delivered across sites, limited diversity among trial participants, and difficulty separating the effects of the drug itself from the effects of the accompanying psychotherapy. The committee had also raised concerns about cardiovascular risk and “functional unblinding” the idea that participants and therapists could often tell who had received MDMA versus placebo, potentially skewing results. The fallout was significant. In early 2026, Lykos announced a major restructuring, cutting roughly 75% of its workforce to concentrate its remaining resources on conducting the additional Phase 3 trial the FDA had requested and preparing a future resubmission. As of now, MDMA-assisted therapy has not been approved by the FDA or any other major regulatory body, and MDMA itself remains a Schedule I controlled substance in the United States meaning its use outside an approved research setting remains illegal.
The Future
A Reset, Not Necessarily a Dead End Despite the setback, MDMA research hasn’t stopped it’s recalibrating. Lykos has signaled it intends to continue working with the FDA, conduct the additional trial the agency requested, and pursue resubmission, while MAPS continues its parallel nonprofit work: training therapists internationally, supporting humanitarian projects in high-trauma regions, and partnering with academic institutions. In February 2026, MAPS announced a research partnership with Columbia University to study how practitioners are actually facilitating MDMA-assisted sessions in practice the kind of real-world implementation data regulators have said is currently lacking. Beyond PTSD, MDMA continues to be studied for other psychiatric applications, including anxiety related to life-threatening illness and social anxiety in autistic adults, as well as in couples-based therapy formats for PTSD. Whether any of these indications move forward will likely depend heavily on how the broader regulatory questions around MDMA trial design, therapist training standards, and how to handle the psychotherapy component of “drug-assisted therapy” get resolved. The Lykos rejection has also reshaped strategy across the wider psychedelic medicine field. Companies developing therapies based on psilocybin, LSD, and ketamine have been reassessing their own regulatory approaches in light of the FDA’s specific criticisms, with some observers suggesting the industry may move away from positioning these treatments primarily as “drug plus therapy” packages, given how much that framing complicated the FDA’s review. Voices within the field have largely framed the 2024 – 2025 setback not as a verdict against psychedelic medicine itself, but as a demand that this emerging category meet the same evidentiary bar as any other drug a position reinforced by the FDA’s own 2023 draft guidance on designing clinical trials for psychedelic compounds.
Conclusion MDMA’s relationship with psychiatry
This has now spanned more than a century from an unremarkable industrial chemical, to a quiet aid in 1970s and ’80s therapy rooms, to a banned party drug, to the subject of a high-profile, ultimately unsuccessful bid for FDA approval. The current setback is real, and the additional research the FDA has requested will take years. But the underlying clinical question whether MDMA, used carefully and within a structured therapeutic framework, can help people with severe PTSD when other treatments have failed remains open, and a substantial body of evidence suggests the answer may still be yes. What happens next will depend less on MDMA’s pharmacology, which has been studied for decades, and more on whether researchers can build the kind of rigorous, well-controlled, and reproducible trial data that regulators are now insisting on.